Genetic Analysis of T Cells in Lupus
狼疮 T 细胞的遗传分析
基本信息
- 批准号:6646996
- 负责人:
- 金额:$ 40.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-07-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyte MHC class II antigen antibody formation autoantibody cell cell interaction cell population study cellular pathology disease /disorder model genetically modified animals helper T lymphocyte immune tolerance /unresponsiveness laboratory mouse leukocyte activation /transformation systemic lupus erythematosus tissue /cell culture
项目摘要
DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) is
characterized by IgG autoantibodies to certain intracellular components,
including chromatin and ribonucleoproteins. Several inbred mouse strains also
develop spontaneous lupus, with the same spectrum of autoantibodies. Certain of
these specificities are pathogenic, including those against chromatin that
induce immune-complex glomerulonephritis. Autoantibodies in lupus arise as a
consequence of autoantigen-specific alpha/beta CD4+ T cell help, including T
cells specific for peptides of chromatin-associated proteins. Such autoreactive
T cells bypass normal tolerance mechanisms in the periphery; however, the
mechanism of activation of T cells responsive to self peptides in lupus is
unknown, as are the tissue source(s) of such peptides and the events leading to
autoreactive CD4+ T cell-B cell collaboration with resultant pathogenic
autoantibody production. In this proposal, an in vivo approach will be used to
dissect the mechanisms that lead to peripheral T cell tolerance abrogation and
T cell help for autoantibody production in lupus. It is hypothesized that these
events arise in two stages: first, that lupus T cells have intrinsic (genetic)
defects that render them susceptible to activation after contact with the
ubiquitous self peptide-class II MI-IC complexes that are sufficient for CD4+ T
cell survival in normal animals; second, that such activation, initiating
tolerance loss with polyclonal expansion of autoreactive T cells, leads to
oligoclonal T-B cell collaboration in the setting of specific autoantigen
presentation by autoreactive B cells. The hypothesis will be addressed in two
aims. First, it will be determined if normally displayed (ubiquitous) MHC-self
peptide complexes can activate autoreactive T cells from Fas-intact mice
MRL/+Fas-lpr mice, in comparison to non-autoimmune control T cells. Second, it
will be determined if T cells from MRL/+Fas-lpr mice can provide B cell help in
the setting of autoantigen presentation by autoreactive B cells, an event that
leads to antigen-specific expansion of cells from both lineages. These
objectives fit well within the overall context of this IRPO proposal centered
around developing a better understanding of T cell-B cell interactions during
the development and maintenance of systemic autoimmunity.
描述(申请人提供):系统性红斑狼疮(SLE)
以针对某些细胞内成分的免疫球蛋白自身抗体为特征,
包括染色质和核糖核蛋白。几个近交系小鼠也
发展为自发性狼疮,具有相同的自身抗体谱。确定的
这些特异性是致病的,包括那些针对染色质的特异性
诱导免疫复合型肾小球肾炎。狼疮自身抗体的产生是一种
自身抗原特异性的α/βCD4+T细胞帮助的结果,包括T
染色质相关蛋白多肽的特异性细胞。这种自动反应
T细胞在外周绕过正常的耐受机制;然而,
狼疮自身多肽诱导T细胞活化的机制
未知,以及这些肽的组织来源(S)和导致
自身反应性CD4+T细胞-B细胞协同致病
自身抗体的产生。在这项提案中,将使用体内方法来
剖析导致外周T细胞耐受性降低和
T细胞有助于狼疮自身抗体的产生。据推测,这些
事件发生在两个阶段:第一,狼疮T细胞具有内在的(遗传)
缺陷,使它们在接触到
无处不在的自体多肽II类MI-IC复合体,足以产生CD4+T细胞
细胞在正常动物中的存活;第二,这种激活、启动
自身反应性T细胞多克隆扩增导致耐受性丧失
寡克隆T-B细胞在特异性自身抗原设定中的协同作用
由自身反应性B细胞呈递。这一假说将分两部分阐述。
目标。首先,将确定是否正常显示(无处不在的)MHC-SELF
多肽复合体能激活Fas基因缺失小鼠的自身反应性T细胞
MRL/+Fas-LPR小鼠与非自身免疫对照T细胞比较。第二,它
将确定来自MRL/+Fas-LPR小鼠的T细胞是否能提供B细胞帮助
自身反应性B细胞自身抗原提呈的设定,这一事件
导致两个谱系的细胞抗原特异性扩增。这些
目标完全符合以IRPO为中心的提案的总体背景
围绕着更好地理解T细胞和B细胞之间的相互作用
全身性自身免疫的发展和维持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Edgar Craft其他文献
Joseph Edgar Craft的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Edgar Craft', 18)}}的其他基金
Human and Translational Immunology Training Program
人类和转化免疫学培训计划
- 批准号:
10649548 - 财政年份:2021
- 资助金额:
$ 40.88万 - 项目类别:
Human and Translational Immunology Training Program
人类和转化免疫学培训计划
- 批准号:
10270035 - 财政年份:2021
- 资助金额:
$ 40.88万 - 项目类别:
Human and Translational Immunology Training Program
人类和转化免疫学培训计划
- 批准号:
10474483 - 财政年份:2021
- 资助金额:
$ 40.88万 - 项目类别:
Follicular Helper T Cell Function in Autoimmunity
滤泡辅助 T 细胞在自身免疫中的功能
- 批准号:
10320436 - 财政年份:2018
- 资助金额:
$ 40.88万 - 项目类别:
Follicular Helper T Cell Function in Autoimmunity
滤泡辅助 T 细胞在自身免疫中的功能
- 批准号:
10061557 - 财政年份:2018
- 资助金额:
$ 40.88万 - 项目类别:
相似海外基金
MHC Class II Antigen Presentation In Melanoma: Impact on Immune Recognition
黑色素瘤中 MHC II 类抗原的呈现:对免疫识别的影响
- 批准号:
10674177 - 财政年份:2021
- 资助金额:
$ 40.88万 - 项目类别:
MHC class II antigen presentation in melanoma: impact on immune recognition
黑色素瘤中 MHC II 类抗原呈递:对免疫识别的影响
- 批准号:
10618790 - 财政年份:2021
- 资助金额:
$ 40.88万 - 项目类别:
MHC class II antigen presentation in melanoma: impact on immune recognition
黑色素瘤中 MHC II 类抗原呈递:对免疫识别的影响
- 批准号:
10392325 - 财政年份:2021
- 资助金额:
$ 40.88万 - 项目类别:
VARIATION IN MHC CLASS II ANTIGEN BINDING SITE OF ATLANTIC SALMON, SALMO SALAR
大西洋鲑鱼 SALMO SALAR MHC II 类抗原结合位点的变异
- 批准号:
8360306 - 财政年份:2011
- 资助金额:
$ 40.88万 - 项目类别:
VARIATION IN MHC CLASS II ANTIGEN BINDING SITE OF ATLANTIC SALMON, SALMO SALAR
大西洋鲑鱼 SALMO SALAR MHC II 类抗原结合位点的变异
- 批准号:
8167705 - 财政年份:2010
- 资助金额:
$ 40.88万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
8131116 - 财政年份:2007
- 资助金额:
$ 40.88万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7321929 - 财政年份:2007
- 资助金额:
$ 40.88万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7673392 - 财政年份:2007
- 资助金额:
$ 40.88万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7483748 - 财政年份:2007
- 资助金额:
$ 40.88万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7907767 - 财政年份:2007
- 资助金额:
$ 40.88万 - 项目类别: